The 2023 European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: A Critical Appraisal

SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.

(2023) Seth P. Lerner et al.   JOURNAL OF CLINICAL ONCOLOGY

Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis

(2023) Alexandre R Zlotta et al.   LANCET ONCOLOGY

Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer

(2023) Martin Swinton et al.   JOURNAL OF CLINICAL ONCOLOGY

Oncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy

(2023) Roberto Contieri et al.   European Urology Oncology

Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials

(2021) Ananya Choudhury et al.   LANCET ONCOLOGY

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

(2021) Thomas Powles et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience

(2017) Nicholas J. Giacalone et al.   EUROPEAN UROLOGY